Pinterest • The world’s catalogue of ideas

Strategies Targeting the Hallmarks of Cancer - This figure illustrates some of the many approaches employed in developing therapeutics targeted to the known and emerging hallmarks of cancer. EGFR indicates epidermal growth factor receptor; CTLA4, cytotoxic T lymphocyte-associated antigen 4; mAb, monoclonal antibody; HGF, hepatocyte growth factor; VEGF, vascular endothelial growth factor; PARP, poly-(ADP ribose) polymerase.

from Medpage Today

Cancer Society's Retiring Chief Shares Parting Thoughts

Nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) gene mutation test results before starting treatment, according to a new survey of oncologists in 10 countries.

National Guideline Clearinghouse | Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline.

Extracellular cysteine/cystine redox regulates the p44/p42 MAPK pathway by metalloproteinase-dependent epidermal growth factor receptor sign...

Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline: Journal of Clinical Oncology: Vol 32, No 29


Cetuximab is an epidermal growth factor receptor inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer.


Hyperactive epidermal growth factor receptor (EGFR) signaling and cancer development have been linked.